Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01771705 · ClinicalTrials.gov registry record · NA
NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT01771705 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 40 participants.
The verdict
NCT01771705, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two different ways of monitoring the immune system to determine how to manage the doses of anti-rejection medications.
Interventions
- OTHER Dose adjust group (NFAT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-05-02 |
| Est. Completion | 2017-04-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01771705
The ClinicalTrials.gov registry entry for NCT01771705 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dose adjust group (NFAT) is the first listed.
NCT01771705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01771705 about?
NCT01771705 is a clinical study titled "NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients". The purpose of this study is to compare two different ways of monitoring the immune system to determine how to manage the doses of anti-rejection medications.
What is the current status of trial NCT01771705?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2013-05-02. Estimated completion is 2017-04-17.
What interventions are being tested in trial NCT01771705?
The interventions under investigation include: Dose adjust group (NFAT) (OTHER).
Who is sponsoring clinical trial NCT01771705?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.